乌鸦传媒

R-CHOP plus venetoclax falls short, while R-CHOP with HDAC inhibitor shows promise

Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients

Loretta Nastoupil, MD, leads a discussion on the ECHELON-3 trial results

Ian Flinn, MD, PhD, leads a discussion on the promising early data for zilovertamab vedotin

Ian Flinn leads a discussion on epcoritamab, which was recently FDA approved

Ian Flinn, MD, PhD, leads a discussion on ZUMA-7 and the upcoming ZUMA-23 with the study authors

Ian Flinn, MD, PhD, leads a discussion on the future successors to the current standard of care